Liquidia Corporation

Liquidia Corporation is a clinical-stage biopharma focused on developing and commercializing therapies for pulmonary hypertension and related diseases using its proprietary PRINT® particle engineering platform. Its key achievement is the FDA approval of YUTREPIA™ (treprostinil) inhalation powder for PAH, positioning the company for a transition to a commercial entity. The strategy centers on successfully launching YUTREPIA™, expanding its label into additional pulmonary hypertension indications, and advancing its pipeline of PRINT®-enabled formulations. The company's value is rooted in its unique manufacturing technology, which creates differentiated, patient-friendly drug products.

PRINT® (Particle Replication In Non-wetting Templates) is a proprietary particle engineering platform that enables precise control over the size, shape, and composition of drug particles for optimized delivery via inhalation, injection, or oral routes.

Liquidia competes directly with United Therapeutics' treprostinil franchise, particularly Tyvaso® DPI, in the PAH and PH-ILD markets. Its competitive edge is based on its proprietary PRINT® particle engineering, which may offer pharmacokinetic and dosing advantages. Success requires demonstrating clear clinical or usability benefits to overcome the strong market position and resources of its key competitor.